Marvel Biosciences Corp
XTSX:MRVL

Watchlist Manager
Marvel Biosciences Corp Logo
Marvel Biosciences Corp
XTSX:MRVL
Watchlist
Price: 0.14 CAD Market Closed
Market Cap: CA$8.1m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Peer Comparison

Country Company Market Cap Operating
Margin
CA
Marvel Biosciences Corp
XTSX:MRVL
8.1m CAD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
45.7B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.9B CNY
Loading...
DE
BioNTech SE
NASDAQ:BNTX
28.1B USD
Loading...
DK
Genmab A/S
CSE:GMAB
127.8B DKK
Loading...
US
United Therapeutics Corp
NASDAQ:UTHR
20.1B USD
Loading...
US
Incyte Corp
NASDAQ:INCY
19.9B USD
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
18.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Marvel Biosciences Corp
Glance View

Market Cap
8.1m CAD
Industry
N/A

Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.

MRVL Intrinsic Value
0.002 CAD
Overvaluation 98%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top